Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRG-001 in Hospitalized Severe and Critical COVID-19 Patients
NCT04646603Phase 2Unknown
- Sponsor
- MedRegen LLC
- Start
- Dec 2021
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of MRG-001 in coronavirus disease 2019 (COVID-19), acute respiratory distress syndrome (ARDS), sponsored by MedRegen LLC. Status: unknown.
02
Drugs
MRG-001
03
Conditions
coronavirus disease 2019 (COVID-19)acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT04646603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04646603.